longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Ayr Wellness Inc.

AYRWF

0.00010.00% ( 0.0000 )
Delay Closed: Sep 14, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 0.00, above the reasonable range, cheaper than 2.61% of the time in the past 5 years, and the industry ranks 58/257, the industry Median -1.28.

-0xP/E
$0.00Stock price
-0xP/E
Stock price$0.00

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-0.35x
Typical range
-13.15x–-0.01x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-56.28x14.01%$58.76B
BAYZFUSBayer Aktiengesellschaft
-27.97x--$56.43B
BAYRYUSBayer
-27.79x--$56.08B
VTRSUSViatris
-46.59x110.35%$19.14B
VREOFUSVIREO GROWTH INC
-181.87x--$12.21B
ELANUSElanco Animal Health
-58.12x129.36%$11.57B
AXSMUSAxsome Therap
-59.20x27.32%$11.34B
CURLFUSCuraleaf Holdings, Inc.
-148.44x--$7.72B
BLTEUSBelite Bio
-68.06x29.87%$6.97B
DFTXUSDefinium Therapeutics
-15.29x53.32%$5.41B
EWTXUSEdgewise Therapeutics
-24.57x137.29%$4.85B
MANEUSVeraDermics
-40.74x97.39%$4.25B
AMLXUSAmylyx Pharmaceuticals
-27.76x1.76%$4.22B
ELVNUSEnliven Therapeutics
-37.65x1.17%$3.99B
TARSUSTarsus Pharmaceuticals
-75.49x34.09%$3.51B
MBXUSMBX Biosciences
-27.47x32.19%$2.87B
RGCUSRegencell Bioscience
-403.49x--$2.84B
GPCRUSStructure Therapeutics
-12.76x104.48%$2.74B
PHVSUSPharvaris BV
-13.75x7.70%$2.73B
SUPNUSSupernus Pharma
-21.95x70.59%$2.41B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.